Candida Funding This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 5, 2022 Category: Research Source Type: funding